Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

Oculis’ neuroprotective candidate privosegtor receives US FDA breakthrough therapy designation to treat optic neuritis: Zug, Switzerland Thursday, January 8, 2026, 17:00 Hrs [IS ...

Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing ...

Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...

The strategy summarises the case for change, identifies road safety targets and outlines an approach to monitoring the ...

Holding announced that its neuroprotective candidate Privosegtor was granted breakthrough therapy designation by the U.S. Food and ...

Oculis Holding AG recently reported that its neuroprotective candidate Privosegtor received U.S. FDA Breakthrough Therapy ...

Learn how to create burndown charts to track project progress, improve team performance, and download free templates to get ...

Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases ...

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 ...

NASA's SPHEREx telescope unveiled its first full-sky map of the universe, combining more than 100 infrared observations into ...

The visual system is the part of the central nervous system that is required for visual perception – receiving, processing and interpreting visual information to build a representation of the visual ...